Abstract
Background: The underrepresentation of women in academic medicine at senior level and in leadership positions is well documented. In the United Kingdom, the National Institute for Health Research (NIHR) announced that eligibility for funding for Biomedical Research Centres (BRCs) required at least Silver award status of the Athena SWAN Charter. However, the evidence base for monitoring gender equity (GE) in BRCs is underdeveloped. Methods: An exploratory online survey distributed to an entire population of NIHR Oxford BRC affiliates (N=683) who ranked the importance of 13 markers of GE on a five point Likert scale. Data were summarised using frequencies and descriptive statistics. Interrelationships between the markers and underlying latent dimensions (factors) were determined by exploratory and confirmatory factor analyses. Thematic analysis was used to analyse open-ended comments. Results: The response rate was 36% (243 respondents). Respondents were more frequently female (55%, n=133), aged 41-50 years (33%, n=81), investigators (33%, n=81) and had been affiliated with the BRC for 2-7 years (39.5%, n=96). Participants ranked BRC senior leadership roles and organisational policies on gender equity, as very important, 58% (n=141) and 57% (n=139) respectively. The top two markers ranked as very important by female participants were organisational policies (64.7%, n=86/133) and recruitment and retention (60.9%, n=81/133), whereas male participants ranked leadership development (52.1%, n=50/96) and BRC senior leadership roles (50%, n=48/96) as being very important. The factor analyses showed two distinct latent dimensions: organisational markers and individual markers of GE in BRCs. Open ended comments suggested three key areas of actions: monitoring and benchmarking, organisational support for those with childcare responsibilities, and leadership and Institutional support for GE. Conclusions: The findings suggest a two-factor model of markers of achievement for GE with organisational and individual dimensions. Implementation and sustainability of gender equity requires commitment at senior leadership and organisational policy level.
Competing Interest Statement
HMcS is the Director of the NIHR Oxford Biomedical Research Centre, LRH is Clinical Research Manager, VK is Chief Operating Officer, SGSS is Senior Research Fellow. AMB was the first Director of the NIHR Oxford Biomedical Research Centre.
Funding Statement
This work was funded by the European Unions Horizon 2020 Research and Innovation programme award STARBIOS2 under grant agreement No. 709517 and funded by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the funders i.e. EU, NHS, the NIHR or the Department of Health. The funder had no role in study design, analysis and interpretation of this study.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are reported in the manuscript
